期刊文献+

非小细胞肺癌组织mTOR/P70S6K表达临床意义的探讨 被引量:3

Expression and clinical significance of mTOR/P70S6K in non-small cell lung cancer tissues
原文传递
导出
摘要 目的:分析在非小细胞肺癌(NSCLC)组织中mTOR/P70S6K/RPS6/eIF4G信号转导途径相关基因mTOR、P70S6K、RPS6、eIF4G的表达水平,探讨mTOR/P70S6K/RPS6/eIF4G基因在NSCLC组织中的表达及临床意义。方法:通过外科手术中获取65例NSCLC组织及30例癌旁组织标本,采用逆转录聚合酶链反应(RT-PCR)技术检测肺癌组织及癌旁组织中mTOR、P70S6K、RPS6和eIF4G基因的表达水平。结果:mTOR、P70S6K、RPS6和eIF4G基因在NSCLC组织中的表达水平分别为(0.54±0.36)%、(0.75±0.34)%、(0.82±0.43)%和(0.28±0.59)%,在癌旁组织中的表达水平分别为(0.28±0.21)%、(0.03±0.03)%(、0.07±0.07)%和(0.09±0.17)%,肺癌组织中的表达水平均显著高于癌旁组织。mTOR、P70S6K、RPS6和eIF4G基因的表达水平同NSCLC患者的年龄、性别、病理类型、分化程度及TNM分期没有明显关系。结论:NSCLC中mTOR/P70S6K/RPS6/eIF4G信号转导途径相关基因显著上调,说明该通路在NSCLC中被激活,因而mTOR/P70S6K/RPS6/eIF4G信号转导途径异常活化可能与NSCLC发病机制有关,可作为诊断NSCLC诊断的标志,且联合检测的结果更可靠。 OBJECTIVE: To detect the mRNA expression levels of roTOR, P70S6K, RPS6 and eIF4G genes, the key genes of mTOR/PTOS6K/RPS6/eIF4G signaling pathway, in human NSCLC tissue, and explore the relationship between roTOR/ P70S6K/ RPS6/eIF4G signaling pathway and NSCLC. MESULTS: Lung cancer tissue specimens were obtained from 65 patients. Adjacent-tumor NSCLC tissues from the 30 patients were served as control. The RT-PCR technique was used to de- tect the roTOR, PTOS6K, RPS6 and eIF4G genes expression levels. RESULTS: The average mRNA expression levels of roTOR, P70S6K, RPS6 and eIF4G genes in NSCLC tissues were (0.54±0.36)%, (0.75±0.34)%, (0.82±0.43)% and (0.28±0.59)%, respectively, while the mRNA expression levels of roTOR, P70S6K, RPS6 and eIF4G genes in adjacenttumor tissues were(0.28±0.21)%, (0.03±0.03)%, (0.07± 0.07)% and (0.09 ± 0. 17)%, respectively. All the levels of roTOR, PTOS6K, RPS6, eIF4G genes expressions in NSCLC tissues were significantly higher than that in adjacent-tumor lung tissue. There were not significantly relationship between roTOR, PTOS6K, RPS6, eIF4G genes expression levels and patientsage, gende, pathological type, differentiation and pTNM stage. CONCLUSIONS: It has demonstrated that mTOR/ P70S6K/ RPS6/eIF4G signaling pathway is activated in the tumor cells of NSCLC. The activated roTOR/ PTOS6K/RPS6/eIF4G signaling pathway may be an important role in the pathogenesis of NSCLC.
出处 《中华肿瘤防治杂志》 CAS 2011年第1期32-35,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 非小细胞肺 信号传导 基因表达 carcinoma, non-small cell lung signai transduction geng expression
  • 相关文献

参考文献9

  • 1Pal S K, Figlin R A, Reckamp K L. The role of targeting mare-malian target of rapamycin in lung cancer[J]. Clin Lung Cancer,2008,9(6):340-345.
  • 2Marinov M, Fischer B, Arcaro A. Targeting mTOR signaling inlung cancer[J]. Crit Rev Oncol Hematol, 2007, 63 (2): 172-182.
  • 3Pisick E, Jagadeesh S, Salgia R. Receptor tyrosine kinases andinhibitors in lung cancer[J]. Sci World J, 2004, 6(4) : 589-604.
  • 4Shaw R J, Cantley L C. Ras, PI(3)K and mTOR signalling con-trols tumour cell growth[J]. Nature, 2006, 441 (7092): 424-430.
  • 5Wangpaichitr M, Wu C, You M, et al. Inhibition of mTOR re-stores cisplatin sensitivity through down-regulation of growthand anti apoptotic proteins[J]. Eur J Pharmacol, 2008, 591(1-3):124-127.
  • 6Conde E, Angulo B, Tang M, et al. Molecular context of theEGFR mutations: evidence for the activation of mTOR/S6K sig-naling[J]. Clin Cancer Res, 2006, 12(3):710-717.
  • 7Dudek H, Datta S R, Franke T F, et al. Regulation of neuronalsurvival by the serine-threonine protein kinaseAkt[J]. Science,1997, 275(5300): 661-665.
  • 8Faried L S, Faried A, Kanuma T, et al. Predictive and prognos-tic role of activated mammalian target of rapamycin in cervicalcancer treated with cisplatin-based neoadjuvant chemotherapy[J]. OncolRep, 2006,16(1):57-63.
  • 9Herberger B, Puhalla H, Lehnert M, et al. Activated mammali-an target o{ rapamycin is an adverse prognostic factor in patientwith biliary tract adenocarcinoma[J]. Clin Cancer Res, 2007,13(16):4795-4799.

同被引文献31

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部